Jason D. Smith - Sep 9, 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
General Counsel
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Sep 9, 2024
Transactions value $
-$19,895
Form type
4
Date filed
9/12/2024, 01:51 PM
Previous filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +3.33K +14.24% 26.7K Sep 9, 2024 Direct F1
transaction URGN Ordinary Shares Sale -$19.9K -1.52K -5.69% $13.08 25.2K Sep 9, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -3.33K -33.33% $0.00 6.67K Sep 9, 2024 Ordinary Shares 3.33K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3 The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.